Britain has a well-documented talent for producing world-class science and an equally reliable talent for failing to commercialise it at home. The pattern is familiar enough to have its own vocabulary: the "valley of death," the "scale-up gap," the exodus of promising companies to American acquirers with deeper pockets and more appetite for risk. The British Business Bank's announcement that it has now invested more than £600m directly into UK science and technology scaleups, more in the last nine months than in the previous four years, is a serious attempt to interrupt that cycle. Whether it succeeds depends less on the Bank's balance sheet than on a question it cannot answer alone: whether the NHS is capable of becoming the anchor customer that UK health innovation has never reliably had.

The BBB's acceleration is not merely a funding story. Since October 2025 the Bank has more than doubled its direct equity portfolio to over 50 high-growth companies, completing 18 new investments and 18 follow-on investments in FY25/26 against 12 the year before. Total direct investment rose from £75m to £188m year-on-year, with the strategic plan targeting £400m annually from a wider deployment of approximately £2bn per year into the UK venture capital ecosystem. The portfolio spans life sciences, advanced manufacturing, clean energy, defence, AI and fintech. The explicit intent is to tackle the late-stage capital gap, the point at which UK companies with genuine commercial traction struggle to raise domestically and face a binary choice between selling to foreign acquirers or relocating entirely.

That gap is acute in health technology. UK companies working in diagnostics, genomics, clinical AI, digital therapeutics and health data infrastructure consistently reach Series B or C with validated technology and limited NHS exposure, then find that the domestic institutional capital base cannot support the scale-up they require. The result is a steady transfer of health innovation capability to the United States, often with the intellectual property, the leadership teams, and ultimately the tax revenues following close behind. The BBB is trying to plug that gap with public capital. It is a reasonable intervention, but it operates upstream of the problem it is ultimately trying to solve.

The problem is procurement. The NHS is the largest single potential buyer of health technology in the country, and it has never functioned as an intelligent customer for domestic innovation at scale. Procurement remains fragmented across integrated care systems operating under sustained financial pressure, with risk appetite for unproven technology effectively at zero in most organisations. The Federated Data Platform, awarded to Palantir after a protracted and controversial process, illustrated precisely how difficult it is for the health service to make a major technology commitment even when the political will exists. For smaller, earlier-stage companies backed by the BBB, the path from investment to meaningful NHS contract is rarely clear, rarely fast, and rarely determined by the quality of the technology.

Wes Streeting has made productivity and AI adoption central to his reform agenda, and the infrastructure around NHS England's abolition and reintegration into the Department of Health creates at least a theoretical opportunity to rationalise procurement and establish clearer routes to market for domestic innovators. The question is whether the policy architecture connecting public capital, health-tech development and NHS adoption is being built with sufficient coherence and urgency to matter. So far the signals are mixed. The ambition is stated; the operational pathways remain underspecified.

There is a political dimension worth acknowledging. The BBB's acceleration reflects an implicit industrial strategy, the use of public financial institutions to fill gaps that private markets and government departments have not addressed. That is legitimate. But capital without customers delays the problem rather than resolving it. A UK health-tech company that raises a BBB-backed Series C, builds its technology to NHS-grade specification, and then cannot secure an NHS contract at meaningful scale will eventually find the exit it was trying to avoid. The investment buys time. It does not change the structural dynamic on its own.

The BBB milestone is real, and the shift in pace and scale since autumn 2025 represents a genuine change in the ambition of British industrial policy as applied to innovation. What it cannot do is substitute for the harder reform: making the NHS an organisation that buys domestic innovation early, at scale, and with enough consistency to function as the anchor that allows UK companies to grow without leaving. Until that changes, public capital and private exit will remain uncomfortably close companions.